Despite the great advancements in treatment for Acute Myeloid Leukemia (AML), high relapse rates are still a concern. Immunotherapy may provide an alternative approach to chemotherapy. In fact, the American Society of Clinical Oncology (ASCO) named immunotherapy in cancer as the ‘Advance of the Year’ in its Clinical Cancer Advances 2016 report.
According to Soumaya Karaki et al., cancer vaccines trigger an anti-tumor immune response after immunization with a defined tumor-specific antigen or modified tumor cells. The use of vaccines in AML is still under development. Kazusa Ishii and Austin J. Barrett conducted a review of vaccine therapy in AML. This review was published in Therapeutic Advances in Hematology. They state that there are a few studies in this area of development and the clinical benefits have been unclear. For example, in phase I/II study single epitopes of WT1 and PR1 peptides were given with adjuvant to patients with AML and/or Myelodysplastic Syndrome (MDS) there were huge reductions in Minimal Residual Disease (MRD) through the increase in PR1 and WT1 specific T-cells, although Kazusa Ishii and Austin J. Barrett report that these effects did not correlate to a meaningful clinical response.
Yet, trials using the WT1 peptide alone in 51 patients with MDS and/or AML reviewed by Di Stasi et al., and part of the report by Kazusa Ishii and Austin J. Barrett, demonstrated more promising effects of this vaccine. In terms of tolerability, there were not any safety concerns and, in terms of clinical response, some patients achieved disease-free survival of up to 8 years.
Kazusa Ishii and Austin J. Barrett also reviewed the use of vaccines after Hematopoietic Stem-Cell Transplant (HSCT). They report that this approach has the following benefits:
- A lower tumor burden early after HSCT phase provides an ideal setting for anti-tumor immune responses to take place
- At the time of transplantation, the unique immune setting around, characterized by regulatory T-cell depletion, lymphopenia and the release of interleukins (such as IL-7, IL-15 and IL-21), facilitates the triggering of anti-leukemia immune responses
- HSCT offers the chance to link vaccination with administration of leukemia specific cells, either vaccinating patients post-cell infusion or via donor vaccination
In summary the use of vaccine therapy has potential, nonetheless, authors state there is a need to further investigate this therapy through large randomized clinical trials.